Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.
Clinical implications of KRAS mutations in advanced non-small cell lung cancer remain unclear. We retrospectively evaluated the prognostic and predictive value of KRAS mutations in patients with advanced NSCLC. Among 484 patients with available results for both KRAS and EGFR mutations, 39 (8%) had K...
Main Authors: | Jong-Mu Sun, Deok Won Hwang, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3665805?pdf=render |
Similar Items
-
The Effectiveness of Maintenance Pharmacotherapies for Non-Small Cell Lung Cancer
by: Myung-Ju Ahn, et al.
Published: (2012-01-01) -
The Effectiveness of Maintenance Pharmacotherapies for Non-Small Cell Lung Cancer
by: Myung-Ju Ahn, et al.
Published: (2012-06-01) -
Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations: Are They Different from Those with Common <i>EGFR</i> Mutations?
by: Hyun Ae Jung, et al.
Published: (2020-10-01) -
The prevalence and prognostic value of KRAS co‐mutation subtypes in Chinese advanced non‐small cell lung cancer patients
by: Dongjing Cai, et al.
Published: (2020-01-01) -
Advances of KRAS Mutation in Non-small Cell Lung Cancer
by: Yang LI
Published: (2009-12-01)